<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30103829</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>19</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1479-7364</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>12</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>13</Day>                    </PubDate>                </JournalIssue>                <Title>Human genomics</Title>                <ISOAbbreviation>Hum. Genomics</ISOAbbreviation>            </Journal>            <ArticleTitle>BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.</ArticleTitle>            <Pagination>                <MedlinePgn>39</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s40246-018-0171-5</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Ovarian cancer is the leading cause of death worldwide among gynecologic malignancies. The recent approval of inhibitors of poly (ADP-ribose) polymerase (iPARP) in the treatment of ovarian cancer in the presence of a BRCA1/2 mutation has sparked the analysis of women with such diagnosis, which can further benefit from the detection of carriers in the family. Germline sequence and large rearrangements for BRCA1/2 were tested in 398 consecutive epithelial ovarian cancer (EOC) patients. The aim of this study was to identify the frequency and spectrum of germline BRCA1/2 pathogenic alterations in a cohort of patients with ovarian serous carcinoma, with a view to adequately selecting patients for prevention through family counseling and correlating this frequency with platinum sensitivity as a guidance to identify patients eligible for iPARP in our population.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 96 patients carried a pathogenic germline mutation, accounting for an overall 24.1% mutation incidence. Among mutation carriers, BRCA1 showed 62.5% incidence, BRCA2 rendered 36.5%, and one patient exhibited a mutation in both genes. Three pathogenic mutations were recurrent mutations detected five, three, and four times and represented 12.5% of the mutated samples. Worth highlighting, a 50% mutation incidence was detected when breast and ovarian cancer coexisted in the same patient. Novel mutations amounted to 9.4% of the total mutations, as compared to 4.7% in breast cancer. Forty out of 60 BRCA1 mutations were beyond the ovarian cancer cluster region (OCCR), in stark contrast with 22 out of 36 BRCA2 mutations being inside the OCCR. Taken together, germline BRCA1/2 mutations in EOC patients showed a distinct mutational spectrum compared to our previously published data on breast cancer patients.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In sum, our study provides novel data on ovarian BRCA1/2 mutation prevalence worldwide, enhances adequate patient selection for family counseling and prevention, and sheds light on the benefits of iPARP treatment.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Cardoso</LastName>                    <ForeName>Florencia C</ForeName>                    <Initials>FC</Initials>                    <AffiliationInfo>                        <Affiliation>Genotipificación y Cáncer Hereditario, Centro de Educación Médica e Investigaciones Clínicas &quot;Norberto Quirno&quot; (CEMIC), Galván 4102, C1431FWO, Ciudad Autonoma de Buenos Aires, Argentina.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Goncalves</LastName>                    <ForeName>Susana</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>AstraZeneca Argentina MC, Vedia 3616, C1430DAH, Ciudad Autonoma de Buenos Aires, Argentina.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mele</LastName>                    <ForeName>Pablo G</ForeName>                    <Initials>PG</Initials>                    <AffiliationInfo>                        <Affiliation>Instituto de Investigaciones Biomédicas (INBIOMED), Facultad de Medicina, Universidad de Buenos Aires-CONICET, Paraguay 2155 - Piso 5, C1121ABG, Ciudad Autonoma de Buenos Aires, Argentina.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liria</LastName>                    <ForeName>Natalia C</ForeName>                    <Initials>NC</Initials>                    <AffiliationInfo>                        <Affiliation>Genotipificación y Cáncer Hereditario, Centro de Educación Médica e Investigaciones Clínicas &quot;Norberto Quirno&quot; (CEMIC), Galván 4102, C1431FWO, Ciudad Autonoma de Buenos Aires, Argentina.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sganga</LastName>                    <ForeName>Leonardo</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>AstraZeneca Argentina MC, Vedia 3616, C1430DAH, Ciudad Autonoma de Buenos Aires, Argentina.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Diaz Perez</LastName>                    <ForeName>Ignacio</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>AstraZeneca Argentina MC, Vedia 3616, C1430DAH, Ciudad Autonoma de Buenos Aires, Argentina.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Podesta</LastName>                    <ForeName>Ernesto J</ForeName>                    <Initials>EJ</Initials>                    <AffiliationInfo>                        <Affiliation>Instituto de Investigaciones Biomédicas (INBIOMED), Facultad de Medicina, Universidad de Buenos Aires-CONICET, Paraguay 2155 - Piso 5, C1121ABG, Ciudad Autonoma de Buenos Aires, Argentina.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Solano</LastName>                    <ForeName>Angela R</ForeName>                    <Initials>AR</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-6342-3663</Identifier>                    <AffiliationInfo>                        <Affiliation>Genotipificación y Cáncer Hereditario, Centro de Educación Médica e Investigaciones Clínicas &quot;Norberto Quirno&quot; (CEMIC), Galván 4102, C1431FWO, Ciudad Autonoma de Buenos Aires, Argentina. asolano@cemic.edu.ar.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Instituto de Investigaciones Biomédicas (INBIOMED), Facultad de Medicina, Universidad de Buenos Aires-CONICET, Paraguay 2155 - Piso 5, C1121ABG, Ciudad Autonoma de Buenos Aires, Argentina. asolano@cemic.edu.ar.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>Res. 0515</GrantID>                    <Agency>Instituto Nacional del Cáncer, Ministerio de Salud de la República Argentina</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>13</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Hum Genomics</MedlineTA>            <NlmUniqueID>101202210</NlmUniqueID>            <ISSNLinking>1473-9542</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2012 Jul 20;30(21):2654-63</RefSource>                <PMID Version="1">22711857</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Oncol. 2003 May;22(5):1169-73</RefSource>                <PMID Version="1">12684687</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2015 Dec;154(3):441-53</RefSource>                <PMID Version="1">26564481</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2015 Jan 1;21(1):211-20</RefSource>                <PMID Version="1">25348513</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2010 Aug;122(3):671-83</RefSource>                <PMID Version="1">19851859</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2016 Jan 1;122(1):84-90</RefSource>                <PMID Version="1">26439132</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2008 Jun 15;14(12):3916-25</RefSource>                <PMID Version="1">18559613</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gynecol Oncol. 2012 Feb;124(2):236-43</RefSource>                <PMID Version="1">22044689</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hum Mutat. 2000 Jul;16(1):88-9</RefSource>                <PMID Version="1">10874312</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2015 Nov 1;33(31):3660-7</RefSource>                <PMID Version="1">26324357</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2016 Jun;60:49-58</RefSource>                <PMID Version="1">27065456</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gynecol Oncol. 2012 Aug;126(2):224-8</RefSource>                <PMID Version="1">22579790</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gynecol Oncol. 2005 Dec;99(3):585-90</RefSource>                <PMID Version="1">16084575</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2016 Jul 24;8(36):60487-60495</RefSource>                <PMID Version="1">28947987</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2013 Jan 16;105(2):141-8</RefSource>                <PMID Version="1">23257159</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2011 Oct 12;306(14):1557-65</RefSource>                <PMID Version="1">21990299</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hum Mutat. 2002 Mar;19(3):307-8</RefSource>                <PMID Version="1">11857749</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2014 Feb 1;20(3):764-75</RefSource>                <PMID Version="1">24240112</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genet Med. 2015 May;17(5):405-24</RefSource>                <PMID Version="1">25741868</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2011 May;22(5):1127-32</RefSource>                <PMID Version="1">21084428</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gynecol Oncol. 2012 Jun;125(3):677-82</RefSource>                <PMID Version="1">22406760</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2011 Jun;22(6):1346-52</RefSource>                <PMID Version="1">21228333</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2010 Jul 24;376(9737):245-51</RefSource>                <PMID Version="1">20609468</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2015 Oct 1;21(19):4257-61</RefSource>                <PMID Version="1">26187614</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Biochem Suppl. 1995;23:189-99</RefSource>                <PMID Version="1">8747396</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2015 Apr 7;313(13):1347-61</RefSource>                <PMID Version="1">25849179</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2012 Apr 12;366(15):1382-92</RefSource>                <PMID Version="1">22452356</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Springerplus. 2012 Sep 25;1:20</RefSource>                <PMID Version="1">23961350</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2017 May 1;140(9):2051-2059</RefSource>                <PMID Version="1">28176296</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">BRCA1/2 and ovarian cancer</Keyword>            <Keyword MajorTopicYN="N">Ovarian cancer</Keyword>            <Keyword MajorTopicYN="N">iPARP treatment</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30103829</ArticleId>            <ArticleId IdType="doi">10.1186/s40246-018-0171-5</ArticleId>            <ArticleId IdType="pii">10.1186/s40246-018-0171-5</ArticleId>            <ArticleId IdType="pmc">PMC6090818</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>